An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo in Participants With Plaque Psoriasis (POETYK-PSO-3) in Mainland China, Taiwan, and South Korea

Bristol-Myers Squibb (BMS)

Status and phase: Completed; Phase 3

Conditions: Psoriasis

Treatments: Drug: BMS-986165; Other: Placebo

Study type: Interventional

Funder types: Industry

Identifiers

NCT04167462

IM011-065

Details and patient eligibility

About

The purpose of this study is to investigate the experimental medication BMS-986165 compared to placebo in participants with moderate to severe plaque psoriasis in mainland China, Taiwan, and South Korea

Enrollment: 220 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Plaque psoriasis for at least 6 months
• Moderate to severe disease
• Candidate for phototherapy or systemic therapy

Exclusion criteria

• Other forms of psoriasis
• History of recent infection
• Prior exposure to BMS-986165

Other inclusion/exclusion criteria may apply.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

220 participants in 2 patient groups, including a placebo group

Arm A:BMS-986165 oral administration

Experimental group

Treatment:

Drug: BMS-986165

Arm B: Placebo oral administration

Placebo Comparator group

Treatment:

Other: Placebo